ImmunoGen breast cancer treatment shows promising results

Waltham biotech ImmunoGen Inc., which announced today a deal with Novartis worth potentially $250 million, also reported positive clinical data in relation to trastuzumb-DM1, its treatment of breast cancer.

The treatment indicated a 47.8 percent response rate in patients taking T-DM1, compared to a 41.4 percent response rate in patients treated with Herceptin and chemotherapy. T-DM1 also had half the number of serious side effects as the standard Herceptin and chemotherapy treatment, according to ImmunoGen officials.

Disable Cookies per browser:

Note: If you are using a browser that is not listed here, please do a quick internet search on how to block cookies and tracking for your specific browser.

This website uses cookies to ensure you get the best user experience. If you agree to accept these cookies, confirm by clicking the "Ok, I Agree" button. For instructions on how to block cookies from this site, please click the "Give Me More Info" button.